Antonio Pérez-Cardona
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonio Pérez-Cardona has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ana R. Hortal2 shared publications
- Begona Quintana
Laboratorio de Radiaciones Ionizantes y Datación, Departamento de Física Fundamental, Universidad de Salamanca, 37008, Salamanca, Spain
2 shared publications - Bruno Martínez-Haya
BIO-MS group, Department of Physical, Chemical and Natural Systems, Universidad Pablo de Olavide, 41013, Seville, Spain
2 shared publications - Carmen Domínguez-Castillo
GLOBE Institute, University of Copenhagen
2 shared publications - David Villalón Torres
Instituto Andaluz del Patrimonio Histórico
2 shared publications - Eduardo Ferrer Albelda
Universidad de Sevilla
2 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Elsevier in Journal of Archaeological Science
- Vol. 195
Mules in the Antiquity of Southern Iberia revealed from proteomics
- 19 September 2026
- Published by Elsevier in Journal of Archaeological Science
- Vol. 195
Open AccessMules in the Antiquity of Southern Iberia revealed from proteomics
- Open Access
- 2 September 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (10) , e70386
1 H HR‐MAS NMR Metabolomics in Combination With Transcriptomic Correlation Provides New Insights Into Metabolic Heterogeneity Across Breast Cancer Immunohistochemical Subtypes
Advances in molecular characterization have significantly redefined our understanding of breast tumor heterogeneity, enabling improved diagnostics and the development of tailored therapeutic strategies. In particular, integrative omics approaches offer a broader scope for exploring the molecular and biochemical complexity of breast cancer. Notably, metabolomics through high‐resolution magic angle spinning (HR‐MAS) NMR spectroscopy enables nondestructive metabolic profiling of intact tissue samples, preserving the native biochemical context and offering unique potential for refining breast cancer subtyping and gaining deeper insight into disease biology. However, the reproducibility and comparability of HR‐MAS‐based metabolomics across studies are still limited by methodological variations, underscoring the need for standardized and reliable protocols to manage the complexity of breast cancer tissue spectra. In this study, LCModel analysis in combination with the Electronic REference To access In vivo Concentrations (ERETIC2) method as a quantitative reference was implemented for absolute metabolite quantification of breast cancer samples, providing a robust metabolic profiling approach. Generalized linear models were applied to evaluate the associations between quantified metabolites and tumor immunohistochemical classification, and transcriptomic correlation analysis was used to explore gene expression profiles underlying the observed metabolic alterations. A total of 27 metabolites were quantified from breast tumor samples spanning the Luminal A, Luminal B (human epidermal growth factor receptor 2–negative, HER2−), Luminal B (HER2+), and triple‐negative breast cancer (TNBC) subtypes. Strong positive associations were observed between phosphocholine (PCho), betaine (Bet), total choline (tCho), and total creatine (tCr) and immunohistochemical subtype, whereas alanine, glucose, and myo‐inositol showed negative associations. Notably, Luminal B (HER2−) tumors exhibited the highest PCho levels, linked to upregulated expression of choline kinase alpha (CHKA) and other enzymes of the Kennedy pathway. In contrast, Luminal B (HER2+) tumors exhibited elevated levels of alanine (Ala), glucose (Glc), and myo‐inositol (Ins), indicating distinct metabolic reprogramming within the luminal subgroups. Additionally, this study highlights the potential role of betaine (Bet) in interconnecting metabolic and epigenetic pathways in breast cancer, as its concentrations were found to vary across subtypes and correlate with genes involved in fatty acid metabolism, DNA methylation, and estrogen signaling. Robust HR‐MAS NMR profiling captured subtype‐dependent metabolic signatures, and integrative analysis with transcriptomics identified gene expression differences associated with these signatures, thereby advancing the understanding of breast cancer heterogeneity.
- 2 September 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (10) , e70386
Open Access1 H HR‐MAS NMR Metabolomics in Combination With Transcriptomic Correlation Provides New Insights Into Metabolic Heterogeneity Across Breast Cancer Immunohistochemical Subtypes
Advances in molecular characterization have significantly redefined our understanding of breast tumor heterogeneity, enabling improved diagnostics and the development of tailored therapeutic strategies. In particular, integrative omics approaches offer a broader scope for exploring the molecular and biochemical complexity of breast cancer. Notably, metabolomics through high‐resolution magic angle spinning (HR‐MAS) NMR spectroscopy enables nondestructive metabolic profiling of intact tissue samples, preserving the native biochemical context and offering unique potential for refining breast cancer subtyping and gaining deeper insight into disease biology. However, the reproducibility and comparability of HR‐MAS‐based metabolomics across studies are still limited by methodological variations, underscoring the need for standardized and reliable protocols to manage the complexity of breast cancer tissue spectra. In this study, LCModel analysis in combination with the Electronic REference To access In vivo Concentrations (ERETIC2) method as a quantitative reference was implemented for absolute metabolite quantification of breast cancer samples, providing a robust metabolic profiling approach. Generalized linear models were applied to evaluate the associations between quantified metabolites and tumor immunohistochemical classification, and transcriptomic correlation analysis was used to explore gene expression profiles underlying the observed metabolic alterations. A total of 27 metabolites were quantified from breast tumor samples spanning the Luminal A, Luminal B (human epidermal growth factor receptor 2–negative, HER2−), Luminal B (HER2+), and triple‐negative breast cancer (TNBC) subtypes. Strong positive associations were observed between phosphocholine (PCho), betaine (Bet), total choline (tCho), and total creatine (tCr) and immunohistochemical subtype, whereas alanine, glucose, and myo‐inositol showed negative associations. Notably, Luminal B (HER2−) tumors exhibited the highest PCho levels, linked to upregulated expression of choline kinase alpha (CHKA) and other enzymes of the Kennedy pathway. In contrast, Luminal B (HER2+) tumors exhibited elevated levels of alanine (Ala), glucose (Glc), and myo‐inositol (Ins), indicating distinct metabolic reprogramming within the luminal subgroups. Additionally, this study highlights the potential role of betaine (Bet) in interconnecting metabolic and epigenetic pathways in breast cancer, as its concentrations were found to vary across subtypes and correlate with genes involved in fatty acid metabolism, DNA methylation, and estrogen signaling. Robust HR‐MAS NMR profiling captured subtype‐dependent metabolic signatures, and integrative analysis with transcriptomics identified gene expression differences associated with these signatures, thereby advancing the understanding of breast cancer heterogeneity.
- Open Access
- 12 May 2026
- Published by Elsevier in SSRN Electronic Journal
Mules in the Antiquity of Southern Iberia revealed from proteomics
The management of equids in the Iberian Peninsula during the Iron Age (first millennium BCE) provides a key archaeological context for investigating the emerging stages of confluent breeding of horses (Equus caballus) and donkeys (Equus asinus). This scenario provided the earliest historical setting in Iberia conducive to the deliberate and systematic production of hybrids, with significant cultural and economic implications. In this study, high‑resolution mass‑spectrometry‑based palaeoproteomics is employed to investigate the presence of equids and to identify molecular signatures of hybridization in the archaeological record of Southern Iberia. The material analyzed spans from the Phoenician‑Punic colonization of the Iron Age to the Roman period and Late Antiquity (7th century BCE to 6th century CE). A systematic reassessment of collagen peptide biomarkers is presented, based on alignments of the corresponding coding DNA sequences, enabling the identification of reliable heterozygous markers diagnostic of equid hybrids. This approach provides a generally applicable analytical framework for the molecular detection of hybrid individuals in archaeological assemblages. The earliest hybrid specimen identified, dated to 543–409 cal BCE, derives from a pre‑Roman Iron Age context in the lower Guadalquivir River basin and constitutes the earliest direct biomolecular evidence to date for mule breeding in the region. The results demonstrate the value of palaeoproteomics as a complementary tool to osteomorphological analysis, to refine reconstructions of past animal husbandry practices and hybrid management strategies in complex archaeological contexts.
- 12 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMules in the Antiquity of Southern Iberia revealed from proteomics
The management of equids in the Iberian Peninsula during the Iron Age (first millennium BCE) provides a key archaeological context for investigating the emerging stages of confluent breeding of horses (Equus caballus) and donkeys (Equus asinus). This scenario provided the earliest historical setting in Iberia conducive to the deliberate and systematic production of hybrids, with significant cultural and economic implications. In this study, high‑resolution mass‑spectrometry‑based palaeoproteomics is employed to investigate the presence of equids and to identify molecular signatures of hybridization in the archaeological record of Southern Iberia. The material analyzed spans from the Phoenician‑Punic colonization of the Iron Age to the Roman period and Late Antiquity (7th century BCE to 6th century CE). A systematic reassessment of collagen peptide biomarkers is presented, based on alignments of the corresponding coding DNA sequences, enabling the identification of reliable heterozygous markers diagnostic of equid hybrids. This approach provides a generally applicable analytical framework for the molecular detection of hybrid individuals in archaeological assemblages. The earliest hybrid specimen identified, dated to 543–409 cal BCE, derives from a pre‑Roman Iron Age context in the lower Guadalquivir River basin and constitutes the earliest direct biomolecular evidence to date for mule breeding in the region. The results demonstrate the value of palaeoproteomics as a complementary tool to osteomorphological analysis, to refine reconstructions of past animal husbandry practices and hybrid management strategies in complex archaeological contexts.